efgartigimod administration
Phase 3
efgartigimod administration is one of 2 therapeutic programs targeting Myasthaenia Gravis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
2 competitors in Myasthaenia Gravis
#DrugCompanyPhaseTrials
1Vyvgart
ArgenxPhase 3
efgartigimod administration
CClinique Neuro-Outaouais
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for efgartigimod administration. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- CClinique Neuro-Outaouais